Physician profile
Sanjeev Kumar
NPI 1114954823
$1,734.03
in general payments reported to CMS, 2019-2025
16 companies · $31.53 in 2025
The $31.53 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.63 · 2024: $1,668 · 2025: $31.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,030 · Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,029.56 |
| Food and Beverage | $669.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $1,029.56 | 2024 | Rytary |
| Alnylam Pharmaceuticals INC. | $104.96 | 2024 | Onpattro, Amvuttra |
| Abbvie INC. | $102.50 | 2021-2025 | |
| Eisai INC. | $78.74 | 2024 | |
| Mdd US Operations, LLC | $77.74 | 2024 | Gocovri, Apokyn |
| Ucb, INC. | $60.74 | 2024 | Nayzilam, Briviact |
| Jazz Pharmaceuticals INC. | $55.26 | 2024 | |
| Biogen, INC. | $39.83 | 2024 | Tysabri, Vumerity, Avonex |
| Kyowa Kirin, INC. | $34.97 | 2024 | Nourianz |
| Microtransponder, INC. | $32.53 | 2024 | |
| Lundbeck LLC | $26.26 | 2024 | Vyepti |
| Banner Life Sciences, LLC | $24.08 | 2024 | |
| Ge Healthcare | $19.57 | 2024 | |
| Amgen INC. | $18.27 | 2024 | Uplizna |
| Novartis Pharmaceuticals Corporation | $15.46 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.